April - June 2009

June 29, 2009		Takeda Submitted an Application for an Additional Indication of Alogliptin for Combination Therapy with Thiazolidinediones, and a New Drug Application of Fixed-Dose Combination of Alogliptin and Pioglitazone HCl in Japan
June 27, 2009		Takeda Receives FDA Complete Response Letter for Alogliptin, An Investigational Treatment for Type 2 Diabetes
June 25, 2009		Takeda Announces Changes in Board Membership and Management Legal Department
June 25, 2009		Notice Concerning Stock Options (Stock Acquisition Rights) for Members of the Board of Directors
June 23, 2009		Takeda Announces Completion of Tender Offer for All Outstanding Shares of IDM Pharma, Inc.
June 23, 2009		Takeda Establishes "Takeda Global Advisory Board"
June 23, 2009		Takeda's Investigational Compound TAK-536 for Treatment of Hypertension Enters into Phase 3 Clinical Trials in Japan
June 18, 2009		New Dosage Combination of Blopress® and diuretic Launched in First European Market
June 8, 2009		Update on Lu AA21004 clinical development programme in major depressive disorder (MDD)
June 4, 2009		Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filing in Europe
May 26, 2009		Takeda to License Vaccine for Haemophilus Influenzae Type B from Novartis
May 20, 2009		Takeda to renovate its Kyoto Herbal Garden
May 18, 2009		Takeda to Acquire IDM Pharma, Adding Mepact (Mifamurtide), The First Treatment Approved for Osteosarcoma in More Than 20 Years, to Its Oncology Franchise
May 14, 2009		FDA Approves ACTOplus met® XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
May 7, 2009		Takeda to Start Sales and Marketing Operation in Portugal
May 7, 2009		Takeda to integrate its two manufacturing operations in Ireland
April 27, 2009		Notice of Retirement of a Legal Representative of the Company
April 23, 2009		Lancet Publishes Phase 3 Clinical Data on Basen®
April 21, 2009		Discontinuation of Development of TAK-379 for Treatment of Diabetes
April 15, 2009		Takeda Participates in the United Nations Global Compact
April 9, 2009		Nature Publishes Pre-clinical Data on an Inhibitor of a Novel Target Discovered by Millennium